cytotoxic T cells
Showing 1 - 25 of >10,000
Hodgkin Disease, Non-Hodgkin Lymphoma, Severe Chronic Active Epstein Barr Virus Trial in Houston (MABEL CTLs, Cyclophosphamide,
Recruiting
- Hodgkin Disease
- +5 more
- MABEL CTLs
- +2 more
-
Houston, Texas
- +1 more
Jan 13, 2023
Epithelial Ovarian Cancer, Ovarian Carcinoma Trial in Nijmegen (XP-DC vaccinations)
Not yet recruiting
- Epithelial Ovarian Cancer
- Ovarian Carcinoma
- XP-DC vaccinations
-
Nijmegen, Gelderland, NetherlandsRadboud University Medical Center
Mar 6, 2023
Epstein-Barr Virus Infections, Adenovirus, Cytomegalovirus Infections Trial in Milwaukee (Cytotoxic T Lymphocytes)
Completed
- Epstein-Barr Virus Infections
- +2 more
- Cytotoxic T Lymphocytes
-
Milwaukee, WisconsinMedical College of Wisconsin
Oct 21, 2021
BK Polyomavirus Trial in Philadelphia (BK-virus specific CTLs)
Recruiting
- BK Polyomavirus
- BK-virus specific CTLs
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
Mar 15, 2022
Cytomegalovirus Infections, Primary Immune Deficiency Disorder Trial in United States (viral specific cytotoxic t-lymphocytes)
Recruiting
- Cytomegalovirus Infections
- Primary Immune Deficiency Disorder
- viral specific cytotoxic t-lymphocytes
-
Los Angeles, California
- +7 more
Sep 27, 2022
Serologically Active Adult Systemic Lupus Erythematosus Trial in Nantes, Paris (Autologous EBV specific CTL infusion)
Terminated
- Serologically Active Adult Systemic Lupus Erythematosus
- Autologous EBV specific CTL infusion
-
Nantes, France
- +2 more
Mar 24, 2022
HIV Trial in Boston (Lymphocytes, Activated)
Completed
- HIV Infections
- Lymphocytes, Activated
-
Boston, MassachusettsNew England Med Ctr / Tufts Univ
Oct 27, 2021
EBV Lymphoma, Post-transplant Lymphoproliferative Disease (PTLD) Trial in Switzerland (Donor-derived ex-vivo expanded EBV Tscm
Not yet recruiting
- EBV Lymphoma
- Post-transplant Lymphoproliferative Disease (PTLD)
- Donor-derived ex-vivo expanded EBV Tscm CTL
-
Basel, Switzerland
- +7 more
Jan 25, 2023
Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor, Symptomatic COVID-19 Infection Laboratory-Confirmed Trial in
Recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- +2 more
- SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes
-
Houston, TexasM D Anderson Cancer Center
Jul 13, 2022
Acute Lymphocytic Leukemia, Lymphoma Trial in New York (Biological/Genetically Modified T cells, Cyclophosphamide-based chemo)
Active, not recruiting
- Acute Lymphocytic Leukemia
- Lymphoma
- Biological/Genetically Modified T cells
- Cyclophosphamide-based chemotherapy
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jan 3, 2023
Hodgkin's Disease, Non-Hodgkin's Lymphoma, Lymphoproliferative Disease Trial in Houston (EBV-specific T cells: A, EBV-specific T
Recruiting
- Hodgkin's Disease
- +3 more
- EBV-specific T cells: A
- EBV-specific T cells: B
-
Houston, Texas
- +1 more
Jun 28, 2022
Covid19 Trial in Philadelphia (Cytotoxic T Lymphocytes)
Active, not recruiting
- Covid19
- Cytotoxic T Lymphocytes
-
Philadelphia, PennsylvaniaThomas Jefferson University
Aug 15, 2022
Pancreatic Cancer Trial in Houston (multiTAA specific T cells)
Active, not recruiting
- Pancreatic Cancer
- multiTAA specific T cells
-
Houston, Texas
- +2 more
Feb 7, 2022
Metastatic Malignant Tumor in the Liver, Metastatic Uveal Melanoma Trial in Houston (Aldesleukin, Autologous CD8+
Active, not recruiting
- Metastatic Malignant Neoplasm in the Liver
- Metastatic Uveal Melanoma
- Aldesleukin
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jan 20, 2023
Metastatic Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7 Trial in Houston (biological, drug, other)
Active, not recruiting
- Metastatic Melanoma
- Stage IV Cutaneous Melanoma AJCC v6 and v7
- Aldesleukin
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Feb 2, 2022
Viral Infection, Primary Immune Deficiency Disorder Trial in United States (BK CTL)
Recruiting
- Viral Infection
- Primary Immune Deficiency Disorder
- BK CTL
-
San Francisco, California
- +5 more
Feb 19, 2021
Recurrent Glioblastoma, Refractory Glioblastoma Trial in Duarte (IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory
Recruiting
- Recurrent Glioblastoma
- Refractory Glioblastoma
- IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells
- +4 more
-
Duarte, CaliforniaCity of Hope Medical Center
Oct 29, 2021
EBV Lymphomas, EBV-associated Malignancies Trial (EBV-specific T-cells)
Withdrawn
- EBV Lymphomas
- EBV-associated Malignancies
- EBV-specific T-cells
- (no location specified)
Jun 9, 2020
Hodgkins Lymphoma, Non Hodgkins Lymphoma Trial in Houston (TAA-specific CTLs)
Recruiting
- Hodgkins Lymphoma
- Non Hodgkins Lymphoma
- TAA-specific CTLs
-
Houston, TexasTexas Children's Hospital
Jul 14, 2022
Multiple Myeloma Trial in Houston (TAA-specific CTLs, TAA-specific CTLs- fixed dose)
Recruiting
- Multiple Myeloma
- TAA-specific CTLs
- TAA-specific CTLs- fixed dose
-
Houston, TexasHouston Methodist Hospital
Nov 11, 2022
HER2 Positive Advanced Solid Tumors Trial (HypoSti.CAR-HER2 T cells, Albumin-bound paclitaxel, Cyclophosphamide)
Not yet recruiting
- HER2 Positive Advanced Solid Tumors
- HypoSti.CAR-HER2 T cells
- +2 more
- (no location specified)
Jan 12, 2023
Cellular and Humoral Immunity to COVID-19 in Moscow Residents
Recruiting
- Covid19
- Respiratory Viral Infection
- SARS-CoV-2 specific IgM and IgG detection
- +2 more
-
Moscow, Russian FederationClinical City Hospital named after I.V. Davydovsky of Moscow Dep
May 21, 2021
CTLA4 Haploinsufficency, Chronic Cytopenia Trial run by the National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting
- CTLA4 Haploinsufficency
- Chronic Cytopenia
- abatacept
- Placebo
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 24, 2022
Diffuse Hemispheric Glioma, H3 G34-Mutant Trial in Los Angeles (biological, procedure, drug)
Not yet recruiting
- Diffuse Hemispheric Glioma, H3 G34-Mutant
- Dendritic Cell Tumor Peptide Vaccine
- +6 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Jul 13, 2022